Otsuka Pharmaceutical
Otsuka Pharmaceutical Co., Ltd., commonly referred to as Otsuka, is a leading global healthcare company headquartered in Japan. Established in 1964, Otsuka has made significant strides in the pharmaceutical and nutraceutical industries, focusing on innovative solutions for mental health, oncology, and general healthcare. With a strong presence in regions such as North America, Europe, and Asia, Otsuka is renowned for its unique products, including the antipsychotic medication Abilify and the hydration solution Pocari Sweat. The company’s commitment to research and development has positioned it as a pioneer in addressing unmet medical needs. Otsuka's dedication to innovation and patient care has earned it a notable reputation in the global market, making it a key player in the pharmaceutical landscape.
DitchCarbon Score
How does Otsuka Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Chemicals industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Otsuka Pharmaceutical's score of 56 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Otsuka Pharmaceutical's reported carbon emissions
In 2023, Otsuka Pharmaceutical reported total carbon emissions of approximately 123,190,000 kg CO2e for Scope 1 and 30,537,000 kg CO2e for Scope 2. The company has also disclosed significant Scope 3 emissions, including 66,464,600 kg CO2e from purchased goods and services, 79,728,000 kg CO2e from the use of sold products, and various other categories contributing to a comprehensive carbon footprint. Otsuka has set ambitious climate commitments, aiming for "Net Zero" emissions by 2050. This long-term goal is part of their 2050 Environmental Vision, which seeks to reduce the total environmental impact of their business activities to zero. To support this vision, they are implementing an integrated energy service structure under a retail electricity provider model, which is expected to enhance their sustainability efforts across all scopes of emissions. The company has demonstrated a proactive approach to climate action, with a focus on reducing emissions across all scopes, including significant contributions from Scope 3, which often represents the largest share of a company's carbon footprint. Otsuka's commitment to sustainability reflects its dedication to addressing climate change and minimising its environmental impact.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2011 | 2012 | 2017 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 285,728,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 116,816,000 | 000,000,000 | - | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 402,544,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Otsuka Pharmaceutical is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
